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Introduction
Membrane fusion is involved in a large number of biological processes in which contents are brought across the membrane. Membrane fusion is highly regulated by specific proteins. In addition, lipid composition is also a determining factor for membrane fusion. For infection by enveloped viruses, the membrane fusion step during virus entry must ensure that the virus genome is uncircuitously delivered to the right location within the host cell. For instance, the entry pathway of influenza virus, a negative strand RNA virus that replicates in the nucleus, was followed by live imaging 1 . Binding of the viral host receptor recognition protein is the first step in the entry process. The attached virus particle is internalized in an endosome and trafficked to a location near the nucleus. There are three stages in the transport process. In the first stage, the virus-bearing endosome moves on the actin filaments, followed by dynein-directed translocation to the perinuclear region in the second stage. The third stage is an intermittent movement involving microtubule-based motilities in the perinuclear region where acidification of the endosomal interior occurs. Membrane fusion takes place in a short time frame at the end of the trafficking. Along the pathway, host proteins that interact with the virus-bearing endosomes, such as Rab5/Rab7 and SNAREs, are recruited to the endosome. Rab5 regulates the functions of early endosomes and Rab7 regulates the functions of late endosomes on which the entry of influenza virus is dependent 2 . Before fusion takes place, SNARE complexes must be assembled on the endosomes 3 . UV-radiation resistance-associated gene (UNRAG), an autophagic tumor suppressor, has been shown to be involved in the assembly of the SNARE complexes to promote viral fusion with the later endosomes 4 . It is clear that the fusion of the viral envelope membrane with the endosomal membrane during entry is highly regulated by host proteins associated with the endosomal membrane. The endocytic virus can program the endosomes to recruit specific cognate SNARE proteins onto the target membrane 4 . This membrane fusion process is not between two lipid vesicles without regulatory proteins.
Changing the membrane structure is an effective way to inhibit viral fusion.
The interferon-induced transmembrane proteins (IFITMs) have been shown to be membrane associated proteins and restrict virus infection [5] [6] [7] [8] . They assert their antiviral effects by changing the properties of the cellular membrane. IFITM3 was shown to be targeted to endosomes through its N-terminal region 9, 10 . IFITM3 is a type II transmembrane protein with a N-terminal intramembrane domain (IM1) and a C-terminal transmembrane domain (TM2) flanking a conserved intracellular loop (CIL) 8 . Overexpression of IFITM proteins increased the lipid order, making the membrane less fluidized, which could be reversed by addition of oleic acid that generates negative spontaneous curvature 7 . IFITM proteins also promote accumulation of cholesterol in the late endosomes 11 . The exact step at which IFITM3 inhibits membrane fusion was recently shown to be the pore expansion by altering the cytoplasmic leaflet 12 . The accumulated data suggest that restriction of the fluidity of the cellular membrane by IFITM proteins is an effective mechanism to block viral membrane fusion with the endosomal membrane.
Small molecule inhibitors have been shown to inhibit membrane fusion of influenza virus. A number of inhibitor compounds can block conformational changes of influenza virus hemagglutinin (HA), which is required for HA to induce viral membrane fusion 13 . However, these inhibitors are HA subtype-specific. Some inhibitors worked on H1 (e.g. RO5464466), or H1-H2 (e.g. BYM-27709, CL 61917 and Stachyflin), or H3 (e.g. TBHQ, and 4c), respectively. Other fusion inhibitors directly bind in the envelope and block viral fusion with cellular membranes 14, 15 . These compounds appear to change the structure of the lipid envelope.
A potent fusion inhibitor, (Z)-3-(bicyclo[2.2.1]heptan-2-yl)-5-((5-(4'chlorophenyl)-3-(3-(piperazin-1-yl)pentyl)furan-2-yl)-methylene)-2thioxothiazolidin-4-one, (named compound 136) was shown to block fusion of the viral envelope with the cellular membrane 16 . In this study, we show that 136 reduces the fusogenicity of influenza virus envelope. 136 appears to alter the structure of the viral membrane so it could not fuse with the more rigid endosomal membrane as shown by electron microscopic images of lipidinfluenza virus fusion, in contrast to IFITM proteins that restrict the fluidity of the cellular membrane to block fusion.
Results

Crystal structure
In previous studies, a potent fusion inhibitor, compound 136, was shown to inhibit influenza virus infection (X-31) with an EC 50 value of 50 picomolar and a selectivity index of 1x10 6 16 . Because of the high potency and selectivity index of 136, further in vitro characterization was carried out. The crystal structure of a compound (7937) that represents the main 136 body indicates that compound 136 has a rigid configuration and has a similar shape as cholesterol, except for the flexible linker ( Figure 1 , Supplementary Figure S1 , Supplemental Table S1 ).
Hemolysis
In the fusion model proposed by Lee 17 , scission of the target membrane occurs prior to lipid mixing with influenza virus. Red blood cells (RBCs) have been used to study fusion of influenza virus with authentic plasma membranes. caused hemolysis at a pH of 5.6 or less as anticipated ( Figure 1E ). Influenza virus treated with 136 also induced hemolysis, but to a slightly greater extent at pH 5.2-5.8 ( Figure 1D ). The exact cause for this increase is not clear. We speculate that HA molecules in 136-treated virions may be able to aggregate somewhat more to induce a slightly increased pore size. The same level of hemolysis is achieved at pH 5.0 with DMSO, 211, and 136 treatment indicating that scission of the host cell target membrane is not inhibited. Based on a previous study 16 finding 136 blocks lipid mixing with authentic cellular membranes, we conclude that 136 inhibits viral fusion post scission of the target membrane but prior to lipid mixing.
Electron microscopy
To directly visualize how 136-treated X-31 virus fused in vitro to liposomes, negative stained electron microscopy was performed. As a control, 136-treated virus and liposomes were mixed at pH 7.5 as shown in Figure 2A .
Clearly the virus is intact and appears identical to untreated, DMSO, or 211- Figure 2C ).
Discussion
Fusion inhibition by small molecules is a promising mechanism to target with antiviral agents 18 . Compound 136 was previously shown by live imaging to be a potent inhibitor that prevents fusion of influenza virus with the cellular membrane 16 . Trypsin-digestion studies further revealed that the inhibitors do not destroy the viral envelope, destabilize hemagglutinin (HA), or prevent the low pHinduced conformational change of HA.
The EM images of X-31 virus with and without treatment with 136 revealed two different modes of membrane fusion with liposomes. The virus treated with DMSO or 211 was robust in fusion with liposomes. One virus particle was shown to fuse with multiple liposomes to form large aggregates ( Figure 2B ). On the other hand, the virus treated with 136 appeared to have lost its high fusion potential even though fusion with liposomes was not completely blocked. This observation is consistent with the result from our studies on 136-treated viruses with cellular membranes in which fusion was reduced to 20% of untreated viruses 16 . The 136-treated virus could not fuse with many liposomes to form large fusion aggregates like the 211-treated virus. In cases that aberrant fusion occurred, the glycoproteins were not distributed across the whole membrane ( Figure 2D -2G ). Sometimes 136-treated virus fusion could not proceed to completion (Figure 2E and 2H ). This may reflect how the fusion process was arrested when authentic cellular membranes were used as target membranes 16 .
In vitro studies of 136-treated influenza virus suggests that the structure of the viral envelope was changed by binding of 136 to the virion. The baseline fluorescence of DiD labeled virions was further reduced by treatment with 136 but not 211 or DMSO, suggesting that 136 binds in close proximity to the membrane bound DiD (Figure 3 ). Lipid mixing of DMSO, 136, or 211-treated DiD labeled virus with liposomes occurred to the same extent although the initial rate of lipid mixing was slower in 136-treated samples (Figure 3 ). This observation can be explained by the pattern of the 136-treated virus with liposomes. Since no aggregates or trapped virions were present, the lipid mixing could be initiated simultaneously between a large number of virions and liposomes. The initiation of lipid mixing occurred more slowly at the beginning due to inhibition by 136, but eventually lipid mixing reached the same extent as 211-treated virus. The content exchange between the 136-treated virus and liposomes with encapsulated trypsin was also more complete because of the same reason (Figure 4 ).
During enveloped virus assembly, the virus buds at the host cell membrane. For viruses like influenza virus, the viral glycoproteins and other envelope proteins are concentrated at membrane microdomains 20 . In the released virus progenies, the virus envelope has a lipid composition rich in sphingolipids and cholesterol, which is very different from the cellular membrane 21 . It has been shown that the cholesterol content in the membrane has various effects on the fusion kinetics of enveloped viruses 22 . It is also shown that the transmembrane domains of viral glycoproteins play an important role in the fusogenicity of the viral envelope 23 . The unique structure of the viral envelope is constructed with virus-specific lipid composition and the transmembrane domains of viral glycoproteins 24 . Fusion inhibitors like compound 136 may bind in the viral envelope, reduce fusogenicity of the virus, and block fusion post scission but prior to lipid mixing with cellular membranes.
From previous studies we found that 136 blocks lipid mixing of influenza virus with the endosomal membrane of human lung epithelial cells 16 .
Additionally, when 136-treated influenza virus was fused at the plasma membrane of human lung epithelial cells analogous to the liposome assays performed in this work, lipid mixing was blocked 16 . Here we have narrowed down the step of the fusion pathway blocked by 136 to post scission of the host cell membrane and prior to lipid mixing. In vitro liposome fusion assays revealed that
136-treated viruses lost their high fusion potential and exhibited aberrant fusion
to liposomes with limited distribution of viral glycoproteins. In some instances the 136-treated virions did not complete fusion; instead a neck-like structure between the viral membrane and the liposomal membrane was present. This may reflect how fusion is arrested by 136 at the plasma membrane and endosomal membranes of human lung epithelial cells.
Methods
Crystallization.
A vial in a vial technique was used to crystallize compound 7937. The inner vial contained 0.5 mL of 25 mg/mL 7937 dissolved in chloroform. The outer vial contained 4.5 mL of pentane. The outer vial was sealed then left at room temperature for one week. Large single crystals appeared in the inner vial within 1 week. Crystal were shipped to the X-ray Crystallography Center at Emory University for structure determination.
Cells and viruses.
MDCK-2 cells were cultured in EMEM supplemented with 5% FBS and penicillin/streptomycin. All influenza viruses were grown in MDCK-2 cells.
Influenza virus strain X-31 (H3N2) was amplified by infecting confluent MDCK-2 cells at an MOI of 0.001. Viruses were purified on a 20-50% sucrose gradient by centrifugation for 1.75 hours at 60,000 RCF.
Preparation of liposomes and fluorescently labeled virus.
Similar as in Schmidt et al. 25 , POPC, POPE, and cholesterol were dissolved in chloroform:methanol (2:1) to make stock solutions. Liposomes 1 µL aliquots of inhibitor stocks were added to the wells of a 96 well plate.
As a control 1 µL of DMSO only was added to wells. Next, 100 µL of X-31 virus at 10 8 pfu/mL was added to the wells and mixed. 100 µL of chicken red blood cells in DPBS was added to each well at a final concentration of 1% and incubated at 37˚C for 10 minutes. The plate was subject to centrifugation at 3000 rpm for 2 minutes and the supernatant was removed. To initiate hemolysis, 250 µL of 138 mM NaCl 10 mM citrate, pH 5.0 -6.0, was added to the appropriate wells. To establish the baseline level of hemolysis, 138 mM NaCl 10 mM HEPES, pH 7.5, was added to a well. The plate was placed in an incubator at 37˚C for 10 minutes. Cells were pelleted at 3000 rpm and 200 µL of supernatant was transferred to a new 96 well plate. OD 540 was measured using a Biotek Synergy HT plate reader.
Negative stain electron microscopy.
Equal volume of 10 µg/mL X-31 virus and 250 µg/mL liposomes were mixed, acidified with an aliquot of 50 mM citrate pH 3.0, and incubated for 20 min at 37˚C. Samples were reneutralized with an aliquot of 100 mM Tris pH 10.0 and incubated at 37˚C for 1 hour. 7 µL of sample was applied to a glow discharged carbon coated grid for 30 seconds, blotted with filter paper, stained with 7 µL of 1% phosphotungstic acid pH 7.5 for 20 seconds, and blotted again. Samples were imaged with a FEI Tecnai 12 transmission electron microscope 2.7. Trypsin mixing assay.
Liposomes were prepared as above except 10 mg/mL trypsin was included during hydration and freeze thawing was omitted to preserve enzymatic activity. Excess trypsin that was not encapsulated into liposomes was removed by dialysis and trace amounts of trypsin were removed by passing the liposomes 
